Prognostic value of CTI for major adverse cardiovascular events in patients With ST-elevation myocardial infarction after primary percutaneous coronary intervention - Report - MDSpire
Advertisement
Prognostic value of CTI for major adverse cardiovascular events in patients With ST-elevation myocardial infarction after primary percutaneous coronary intervention
Clinical Report: Evaluating the Prognostic Significance of CTI in STEMI Patients
Overview
This study identifies the C-reactive protein–triglyceride glucose index (CTI) as an independent predictor of major adverse cardiovascular events (MACE) in patients with ST-elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). The association is primarily driven by acute heart failure events, highlighting the need for improved risk stratification in this population.
Background
STEMI is a critical condition leading to significant morbidity and mortality, with PCI being the standard treatment. Despite advancements, many patients experience MACE post-PCI, necessitating better prognostic tools. CTI, a composite biomarker reflecting insulin resistance and systemic inflammation, may enhance risk assessment in STEMI patients.
Data Highlights
Measure
Value
Patients Enrolled
618
MACE Incidence
22.5%
HR for CTI and MACE
1.443 (95% CI: 1.191–1.748, P < 0.001)
Key Findings
CTI is an independent predictor of MACE in STEMI patients post-PCI.
During follow-up, 22.5% of patients experienced MACE.
The association between CTI and MACE is primarily driven by acute heart failure events.
Subgroup analysis shows consistent associations regardless of diabetes status.
CTI provides modest improvement in discrimination and clinical net benefit when added to baseline models.
Clinical Implications
Clinicians should consider CTI as a valuable prognostic tool for assessing MACE risk in STEMI patients undergoing PCI. The findings suggest that monitoring CTI levels may help identify patients at higher risk for acute heart failure post-infarction, allowing for targeted interventions.
Conclusion
CTI serves as a significant prognostic marker for MACE in STEMI patients, emphasizing the importance of integrating metabolic and inflammatory assessments in clinical practice.
